Current medical therapy is not without problems. Both commonly used small molecule and antibody drugs have multiple limitations.
There are several limitations of small molecule drugs:
Meanwhile, there are also multiple limitations of antibody biologics as well:
Challenges of undruggable targets and Protein-Protein Interaction:
Among the most difficult and “undruggable” targets are those which exert their biological function through engagement in intracellular protein-protein interactions.
Flat and extended contact surfaces along with intracellular localization make such target very challenging for antibodies or small molecule drugs to act.
To respond to this unmet medical need, Tavotek has created a new generation of intracellular targeting multicyclic peptides for tissue penetration and modulation of protein-protein interactions.
The design strategy for these MIP molecules are:
Potential advantages of Tavotek’s MIP molecules are:
Copyright © 2020 Tavotek Biotherapeutics - All Rights Reserved.